Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Valeant Pharmaceuticals International Inc (NYSE:VRX)

25.05
Delayed Data
As of Sep 29
 -1.37 / -5.19%
Today’s Change
18.55
Today|||52-Week Range
182.64
-75.36%
Year-to-Date
Better Buy: Valeant Pharmaceuticals International, Inc. vs. Endo International plc
8:06am / MotleyFool.com - Paid Partner Content
Trending Tickers: TWTR, VRX, ENDP, RIG
Sep 26 / TheStreet.com - Paid Partner Content
No Matter Who Becomes President, Valeant Pharmaceuticals Could Lose Pricing Power
Sep 29 / MotleyFool.com - Paid Partner Content
Andrew Left Says Trump and Clinton Agree on Just One Thing
Sep 26 / TheStreet.com - Paid Partner Content
3 Stocks for Growth in 2017
Sep 29 / TheStreet.com - Paid Partner Content
Can You Guess Which Big Pharma Has Raised Its Drug Prices 5 Times Since June 2014?
Sep 26 / MotleyFool.com - Paid Partner Content
Here's Why You Shouldn't Pay Much Attention to Wall Street Analysts' Stock Ratings
Sep 27 / MotleyFool.com - Paid Partner Content
Is Valeant Pharmaceuticals Playing With Fire?
Sep 23 / MotleyFool.com - Paid Partner Content
Clinton, Trump Share Big-Pharma Attack Goals, Andrew Left Says
Sep 26 / TheStreet.com - Paid Partner Content
Valeant Needs Time If It Is to Recover and Rise
Sep 23 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close26.42
Today’s open26.44
Day’s range24.96 - 26.45
Volume17,081,164
Average volume (3 months)26,073,798
Market cap$9.0B
Dividend yield--
Data as of 09/29/2016

Growth & Valuation

Earnings growth (last year)-131.25%
Earnings growth (this year)-35.55%
Earnings growth (next 5 years)+11.00%
Revenue growth (last year)+26.42%
P/E ratioNM
Price/Sales3.32
Price/Book1.53

Competitors

 Today’s
change
Today’s
% change
RDYDr.Reddy's Laborator...-1.65-3.45%
MNKMallinckrodt Plc-3.48-4.80%
SGENSeattle Genetics Inc-2.04-3.69%
JAZZJazz Pharmaceuticals...-2.75-2.19%
Data as of 09/29/2016

Financials

Next reporting dateOctober 17, 2016
EPS forecast (this quarter)$1.79
Annual revenue (last year)$10.4B
Annual profit (last year)-$291.7M
Net profit margin-2.79%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chairman &
Chief Executive Officer
Joseph C. Papa
Chief Financial Officer &
Executive VP-Finance
Paul S. Herendeen
Corporate headquarters
Laval, Quă©bec

Forecasts

Search for Jobs